Clinical Trials Arena is using cookies

We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.

ContinueLearn More X
X

Sylvant (siltuximab) for the Treatment of Multicentric Castleman’s Disease

Drug Name

Sylvant / siltuximab

Developed by

Janssen Biotech

Product Description

Anti-IL-6 chimeric monoclonal antibody

Current Indication

Multicentric Castleman's Disease (MCD)

Market Sector

Haematology

Development Status

Approved in the US and Europe
Expand
Close
Close
Close

Go Top